NeffyTM 1 mg
(epinephrine nasal spray)
Small Device. Big Impact.
Neffy™ is a low-dose intranasal epinephrine nasal spray in clinical development for severe allergic reactions that can lead to anaphylaxis.
Anaphylaxis is a severe, life-threatening allergic reaction that can start ordinarily, progress quickly — as fast as within a couple of minutes — and can be fatal if not treated immediately.
Easy-to-use and needle-free, Neffy may eliminate the anxiety and hesitation associated with using an injection device. With use at the first signs of allergic response, Neffy could provide patients and their families the preventive solution to anaphylactic progression.
Investigational New Drug - Not Available For Commercial Distribution
Neffy™ is a low-dose intranasal epinephrine nasal spray in clinical development for severe allergic reactions that can lead to anaphylaxis.
Anaphylaxis is a severe, life-threatening allergic reaction that can start ordinarily, progress quickly — as fast as within a couple of minutes — and can be fatal if not treated immediately.
Easy-to-use and needle-free, Neffy may eliminate the anxiety and hesitation associated with using an injection device. With use at the first signs of allergic response, Neffy could provide patients and their families the preventive solution to anaphylactic progression.
Investigational New Drug - Not Available For Commercial Distribution
Neffy™ 1 mg (epinephrine nasal spray)
Potential Benefits

Needle-Free
Administration
User-friendly design may enable fast, easy and pain-free epinephrine delivery at the first sign of a severe allergic reaction.

Dependable
Delivery
Developed with Intravail®, an absorption-enhancing technology that enables the reliable and rapid delivery of epinephrine comparable to intra-muscular injection with a low-dose spray into the nose.*

Pocket-Sized
Protection
Small and light enough to carry in a pocket or purse, or on a keychain—anytime, anywhere.



A Life-Threatening Problem
Epinephrine is the first-line therapy for severe allergic reactions, yet more than half of adult patients prescribed autoinjectors don’t use them when needed due to a range of reasons including:- fear of needles
- bulkiness of the device
- lack of proper training
- misconception that epinephrine is only used once symptoms are most severe
A Potentially Life-Changing Advancement
Neffy™ 1 mg (epinephrine nasal spray) is an innovative product in development for the treatment of severe allergic reactions that patients and caregivers may actually use because of its potentially breakthrough features, including:
- quick, easy, needle-free administration
- compact size of device
- Intravail® technology and proprietary formulation which ensures rapid absorption of low-dose epinephrine, with pharmacokinetics/pharmacodynamics comparable to injection*
- proven device that is currently used in the treatment of migraines, seizures, and opioid overdoses
If approved for commercial use, Neffy may be able to support patient preparedness to act quickly and confidently during a crisis, helping to treat severe allergic reactions sooner, when it is most important.
Neffy Device Development Milestones
ARS Discovery of Formulation Technology
FDA Grants Fast Track Designation
Promising Data From EPI 04 Clinical Study
Promising Results From EPI 03 Clinical Study
Results Favor ARS Product in EpiPen Comparison From EPI 07 Clinical Study
ARS Pharmaceuticals Announces Composition of Matter patent for ARS-1
ARS Pharmaceuticals Announces a New Patent on ARS-1
ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for NeffyTM
ARS Announces Acceptance of Market Authorization Application submission to European Medicines Agency for NeffyTM
*Data on File